Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 23 (5) , 391-402
Abstract
Polymyalgia rheumatica (PMR) is a common disorder in the elderly population. The diagnosis is based upon recognition of a clinical syndrome, consisting of pain and stiffness in the shoulder and pelvic girdle, muscle tenderness of the upper and lower limbs and nonspecific somatic complaints. In addition, in most cases the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration are highly elevated. Although PMR and giant cell arteritis (GCA) are commonly regarded as two clinical variations of the same disease, their clinical picture is quite different. Whilst in PMR the musculoskeletal symptoms predominate, the major features of GCA are arterial inflammation and its consequences, which suggests clinical and pathological discrepancies between the two syndromes and important differences with respect to morbidity and mortality. The prognosis of correctly diagnosed PMR is excellent. It is well known that corticosteroid therapy in PMR usually leads to rapid and dramatic improvement of patients’ complaints and returns them to previous functional status. However, prolonged corticosteroid treatment, sometimes for several years, may be necessary to maintain clinical improvement. Despite all the knowledge about the beneficial effects of corticosteroid treatment, data concerning the optimal dosage regimen are lacking. Long-term corticosteroid use can be associated with various adverse events, of which induction of osteoporosis, diabetes mellitus and infection among the worst. A Corticosteroid Side Effect Questionnaire has been shown to dose-dependently detect adverse effects perceived by patients. The European League Against Rheumatism (EULAR) response criteria for PMR comprise a core set of markers for monitoring therapeutic responses in PMR, namely ESR or CRP, the visual analogue scale of patient’s pain and physician’s global assessment, as well as morning stiffness and the ability to elevate the upper limbs. The PMR-disease activity score has been developed on the basis of EULAR response criteria as a means of expressing disease activity as an absolute number. A score 17 is indicative of high disease activity. The PMR-disease activity score has been proven to be highly correlated with patient’s global assessment, patient satisfaction and ESR. It provides an easily applicable and valid tool for disease activity monitoring in patients with PMR. Improved knowledge of disease activity processes, exact monitoring of disease activity and treatment responses, and increased risk-estimation of treatment schedules should ultimately improve the care of patients with PMR.Keywords
This publication has 54 references indexed in Scilit:
- Practice patterns in patients at risk for glucocorticoid-induced osteoporosisOsteoporosis International, 2005
- The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: Influence on clinical subgroups and prognosisSeminars in Arthritis and Rheumatism, 2004
- Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis?QJM: An International Journal of Medicine, 2004
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)Annals of the Rheumatic Diseases, 2002
- Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients.2002
- Polymyalgia rheumatica and temporal arthritis.2000
- Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.1999
- The use of methotrexate in polymyalgia rheumatica.1996
- Myalgic Syndrome with Constitutional EffectsAnnals of the Rheumatic Diseases, 1957